History
  • No items yet
midpage
37 F.4th 160
4th Cir.
2022
Read the full case

Background

  • Eli Lilly sought discovery under 28 U.S.C. § 1782 from Novartis in the Eastern District of Virginia to support patent-invalidity and antitrust defenses/claims in several European proceedings after Novartis acquired a Genentech patent portfolio.
  • The magistrate judge granted Eli Lilly’s § 1782 application and authorized a subpoena; Novartis intervened and moved to quash.
  • The district court vacated the magistrate judge’s order, denied the § 1782 application, and quashed the subpoena, ruling Novartis was not “found” in the district because it lacked a physical presence and, alternatively, that discretionary Intel factors counseled denial.
  • Eli Lilly argued “found” should be coextensive with constitutional personal-jurisdiction standards (International Shoe modern test); Novartis argued “found” requires physical presence or analogous contacts (agents/agents carrying on business or designated agent for process).
  • The Fourth Circuit affirmed the district court, relying on the statutory/textual meaning of “found” as requiring physical presence (or comparable agent presence) and on the district court’s discretionary Intel analysis (circumvention and burden).

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Meaning of “found” in § 1782 “Found” means within a district’s personal jurisdiction (International Shoe standard). “Found” requires physical presence or presence via officers/agents carrying on business (traditional meaning). “Found” requires physical presence/agents carrying on business; statutory/textual meaning controls.
Whether Novartis was “found” in EDVA Novartis had sufficient contacts; thus § 1782 applies. No physical presence or agents carrying on business in EDVA. Novartis was not “found” in EDVA; § 1782’s territorial requirement unmet.
Discretion under Intel Even if statutory requirements met, courts should grant § 1782 to aid foreign proceedings. Denial appropriate where request is burdensome, seeks materials abroad, or attempts to circumvent foreign procedures. District court did not abuse discretion: Intel factors (circumvention, burden) supported denial.

Key Cases Cited

  • Intel Corp. v. Advanced Micro Devices, Inc., 542 U.S. 241 (2004) (district courts have discretion under § 1782; lists four Intel factors)
  • People’s Tobacco Co. v. American Tobacco Co., 246 U.S. 79 (1918) (corporation is “found” where present by officers/agents conducting business)
  • Eastman Kodak Co. v. Southern Photo Materials Co., 273 U.S. 359 (1927) (distinguishes “found” from “transacts business”; “found” implies presence)
  • Neirbo Co. v. Bethlehem Shipbuilding Corp., 308 U.S. 165 (1939) (corporation may be “found” where it consents to suit or appoints an agent)
  • Freeman v. Bee Machine Co., 319 U.S. 448 (1943) (observes “found” does not always mean physical presence; discusses consent/appearance)
  • International Shoe Co. v. Washington, 326 U.S. 310 (1945) (modern due-process personal-jurisdiction standard based on minimum contacts)
  • In re del Valle Ruiz, 939 F.3d 520 (2d Cir. 2019) (held “found” is coextensive with personal-jurisdiction limits under the Due Process Clause)
Read the full case

Case Details

Case Name: Eli Lilly and Company v. Novartis Pharma AG
Court Name: Court of Appeals for the Fourth Circuit
Date Published: Jun 16, 2022
Citations: 37 F.4th 160; 22-1094
Docket Number: 22-1094
Court Abbreviation: 4th Cir.
Log In
    Eli Lilly and Company v. Novartis Pharma AG, 37 F.4th 160